Buprenorphine HCL
Total Payments
$224,724
Transactions
4
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2023 | $77,257 | 1 | 0 |
| 2022 | $95,659 | 2 | 0 |
| 2021 | $51,809 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $147,467 | 3 | 65.6% |
| Unspecified | $77,257 | 1 | 34.4% |
Payments by Type
General
$147,467
3 transactions
Research
$77,257
1 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Opioid / BTOD REMS | Hikma Pharmaceuticals USA | $77,257 | 0 |
Top Doctors Receiving Payments for Buprenorphine HCL
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Winter Park, CO | $224,724 | 4 |
Ad
Manufacturing Companies
- Hikma Pharmaceuticals USA $224,724
Product Information
- Type Drug
- Total Payments $224,724
- Total Doctors 0
- Transactions 4
About Buprenorphine HCL
Buprenorphine HCL is a drug associated with $224,724 in payments to 0 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is Hikma Pharmaceuticals USA.
Payment data is available from 2021 to 2023. In 2023, $77,257 was paid across 1 transactions to 0 doctors.
The most common payment nature for Buprenorphine HCL is "Consulting Fee" ($147,467, 65.6% of total).
Buprenorphine HCL is associated with 1 research study, including "Opioid / BTOD REMS" ($77,257).